

GALAPAGOS

Limited Liability Company ("Naamloze Vennootschap")
With registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, België
Registered with the Register of Legal Entities (Antwerp, division Mechelen)
under number 0466.460.429
(the "Company")

Minutes of the Annual Shareholders' Meeting Held in Mechelen on 26 April 2016

Bureau

The Meeting, which was held at the registered office of the Company, was opened at 2:00 p.m. CET under the chairmanship of Dr Werner Cautreels, Director of the Company and Chairman of the Company's Audit Committee.

The Chairman appointed Mr Xavier Maes, residing at [REDACTED], as Secretary.

The Meeting elected the following persons as Vote Counters:

- Mr J. Adriaenssens, residing at [REDACTED]; and
- Mr J. Bauters, residing at [REDACTED].

The Bureau consists of the Chairman, the Secretary, the Vote Counters and Mr Onno van de Stolpe, managing director (CEO).

Chairman's Statements

The Chairman stated the following:

1 Composition of the Meeting

- (a) **Shareholders** – The Shareholders, whose identity and the number of shares they owned as per the record date (within the meaning of article 536 §2 of the Belgian Companies Code) are mentioned in the attendance list, were present or represented. This attendance list was signed by the relevant Shareholders or their proxy holder and by the members of the Bureau. This attendance list and the proxies mentioned therein shall remain attached to these minutes.

Certain proxies were given by the relevant Shareholder to the Company's General Counsel, who is an employee of the Company but not a member of its Board of Directors or its Executive Committee; the proxy holder received, in each of these cases, specific voting instructions for each agenda item, as a result of which no problems relating to potential conflicts of interests between the relevant Shareholders and the relevant proxy holder can arise. The Bureau acknowledged the validity of all proxies, including those given by telecopy or e-mail (pdf).

The notifications by Shareholders of their intention attend the Shareholders' Meeting were presented to the Bureau. The Bureau acknowledged the validity of all such notifications, including those given by telecopy or e-mail (pdf) and further acknowledges that the delivery by or on behalf of Shareholders of proxies or of certificates evidencing the ownership of shares as per the record date, is to be considered as a notification by the relevant Shareholders of their intention to attend the Shareholders' Meeting, within the meaning of article 536 §2 of the Belgian Companies Code.

Free translation for information purposes only

- (b) **Warrant holders** – One Warrant Holders signed up for this meeting. The identity and number of warrants held as per the record date are mentioned in the attendance list.
- (c) **Directors and Statutory Auditor** – The following Directors were present: and Dr Werner Cautreels, Director and Chairman of the Audit Committee and Mr Onno van de Stolpe, Managing Director (CEO). The other board members were excused. Messrs. Gert Vanhees and Pieter-Jan Van Durme were present on behalf of Deloitte Bedrijfsrevisoren, Statutory Auditor of the Company.

2 Agenda of the Meeting

Ordinary part

1. Communication and discussion of the annual report of the Board of Directors relating to the non-consolidated and consolidated annual accounts of the Company for the financial year ended on 31 December 2015, and of the report of the Statutory Auditor relating to the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2015.

2. Communication and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2015 and approval of the allocation of the annual result as proposed by the Board of Directors.

Proposed resolution: The Shareholders' Meeting resolves to approve the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2015, as well as the allocation of the annual result as proposed by the Board of Directors.

3. Communication and discussion of the report of the Statutory Auditor relating to the consolidated annual accounts of the Company for the financial year ended on 31 December 2015.
4. Communication and discussion of the consolidated annual accounts of the Company for the financial year ended on 31 December 2015.
5. Communication and approval of the remuneration report.

Proposed resolution: The Shareholders' Meeting resolves to approve the remuneration report.

6. Release from liability to be granted to the Directors and the Statutory Auditor for the performance of their duties in the course of the financial year ended 31 December 2015.

Proposed resolution: The Shareholders' Meeting resolves, by separate vote, to release each Director and the Statutory Auditor from any liability arising from the performance of their duties during the last financial year.

7. Remuneration of Directors.

Proposed resolution: Upon recommendation of the Company's Nomination and Remuneration Committee, the Shareholders' Meeting resolves that (a) the compensation (excluding expenses) of the non-executive Directors for the exercise of their mandate during the financial year ending 31 December 2016 is established as follows: (i) Chairman of the Board: €80,000; (ii) other non-executive Board members: €40,000 each; (iii) annual additional compensation for membership of a Board committee: €5,000; (iv) annual additional compensation for the chairmanship of a Board committee: €10,000; and (b) power of attorney is granted to the Board of Directors to determine the total remuneration package of the Managing Director (CEO) for his management function in the Company, it being understood that this remuneration shall include a compensation for the performance of his mandate as a Director of the Company.

8. Offer of warrants.

Proposed resolution: Upon recommendation of the Company's Nomination and Remuneration Committee, the Shareholders' Meeting (i) resolves to offer 100,000 warrants to Mr. Onno van de Stolpe,

15,000 warrants to Dr. Raj Parekh, and 7,500 warrants to each of Dr. Werner Cautreels, Dr. Harrold van Barlingen, Mr. Howard Rowe, Ms. Katrine Bosley and Dr. Christine Mummery, under warrant plans to be created by the Board of Directors for the benefit of Directors, employees and independent consultants of Galapagos and its affiliates within the framework of the authorized capital (jointly "**Warrant Plan 2016**"), the key conditions of which will be in line with previous warrant plans of the Company, (ii) empowers the Managing Director, as well as any other Director as regards the offer to the Managing Director, to implement this offer, and (iii) to the extent required, approves the offer of warrants to members of Galapagos' Executive Committee under Warrant Plan 2016 in accordance with Galapagos' remuneration policy and practices. In accordance with articles 520^{ter} and 556 of the Belgian Companies Code, the Shareholders' Meeting expressly approves the particular provisions of such Warrant Plan 2016 pursuant to which, in exceptional circumstances (including in the event of a change in control of the Company), all 900,000 warrants offered (to the extent accepted) under Warrant Plan 2016 can be exercised early, even before the third anniversary of their award.

The resolutions of this Shareholders' Meeting relating to the issuance of warrants can only be implemented if the Belgian Financial Services and Markets Authority (FSMA) has communicated to the Company that it has no objections to make against the issuance of warrants as set forth in this agenda item.

Special part

9. Application of article 556 of the Belgian Companies Code.

Proposed resolution: In accordance with article 556 of the Belgian Companies Code, the Shareholders' Meeting resolves to approve, and to the extent required, ratify all of the provisions granting rights to third parties which could affect the assets of the Company, or could impose an obligation on the Company, where the exercise of those rights is dependent on a public takeover bid on the shares of the Company or a change of control in respect of the Company, as included in: (a) the License and Collaboration Agreement between Galapagos NV and Gilead Biopharmaceutics Ireland Unlimited Company dated 16 December 2015 (the "**License and Collaboration Agreement**") including, but not limited to, clause 15.6 (*Assignment; Industry Transaction; Acquired Programs*) of the License and Collaboration Agreement, entitling the counterparty (i) in the event of an industry transaction involving the Company, as a result of which a drug company of a certain minimum size acquires control over the Company, to terminate the Company's co-promotion rights, to disband all joint committees and undertake exclusive control of their activities; and (ii) in the event of a change of control as a result of which the Company acquires rights to an alternative product that would violate certain of Company's exclusivity obligations under the License and Collaboration Agreement, to require the Company to either divest or terminate this acquired program; (b) the Sublicense Agreement between Ambion, Inc. as licensor and the Company as licensee dated 18 December 2003 (as amended from time to time, the "**Ambion Sublicense Agreement**") including, but not limited to, section 9.4 (*Change in Ownership or Control*) of the Ambion Sublicense Agreement which requires the Company to obtain the counterparty's prior consent in the event of a change in control over the Company; and (c) Warrant Plan 2013 (B) and Warrant Plan 2014 (B), pursuant to which, in exceptional circumstances (including in the event of a change in control of the Company), all 180,000 warrants outstanding under these warrant plans can be exercised early, even before the third anniversary of their award. The Shareholders' Meeting grants a special power of attorney to each Director of the Company, as well as to Mr. Xavier Maes and Ms. Ellen Lefever, each acting individually and with the power of substitution, to file this resolution with the clerk's office of the Commercial Court of Antwerp, division of Mechelen, in accordance with article 556 of the Belgian Companies Code.

10. Miscellaneous.

3 Convocations for the Meeting

3.1 Convocation of the holders of dematerialized shares and of bearer shares

In accordance with the Belgian Companies Code, the convocations, mentioning the agenda and the proposals of resolutions, have been made by means of the following announcements:

1. in the Belgian State Gazette ("*Belgisch Staatsblad*") of 25 March 2016; and
2. in *De Tijd* of 25 March 2016.

Moreover, the date of the Shareholders' Meeting was announced on the website of Euronext on 25 March 2016 and through a press release circulated by GlobeNewswire on 25 March 2016.

Evidence of these publications was submitted to the Meeting for review and shall be kept at the registered office.

3.2 Publication via the website of the Company

The convocation was also published on the Company's website on 25 March 2016. A print of the publication on the website was submitted to the Meeting for review and shall be kept at the registered office.

3.3 Convocation of the holders of registered shares and registered warrants, of the Directors and of the Statutory Auditor

In accordance with the Belgian Companies Code, the convocations, mentioning the agenda and the proposals of resolutions, were sent by letter dated 26 March 2016 to the holders of registered shares and to the Statutory Auditor, and by e-mail of 25 March 2016 to the warrant holders. A copy of these convocations was submitted to the Meeting for review and shall be kept at the registered office.

The directors waived all notice periods and notice requirements in respect of the annual shareholders' meeting, as well as the right to receive the above-mentioned reports and documents, in accordance with articles 533 and 535 of the Belgian Companies Code and the articles referring thereto.

3.4 Communication to Euronext, FSMA and AFM

The Company is a company that calls on or has called on public savings. The convocation, mentioning the agenda and the proposals of resolutions, has therefore also been communicated to the Financial Services and Markets Authority ("FSMA"), to Euronext and to the Dutch Financial Markets Authority ("AFM"), by e-mail dated 25 March 2016. A printed copy of these communications was submitted to the Meeting for review and shall be kept at the registered office.

4 Right to add agenda items

The Chairman stated that no requests of Shareholders were received to add additional items and/or to include additional proposals of resolutions in the agenda of this General Shareholders' Meeting.

5 Quorum

There are no quorum requirements for the items on the agenda of this Shareholders' Meeting. Consequently, the Meeting can validly deliberate and resolve, irrespective of the number of shares that are present and/or represented.

The capital of the Company is currently represented by 45,968,738 shares.

The attendance list showed that 24,693,265 shares (i.e. 53.72%) were present or represented.

6 Voting right – Majority

The Company has not issued shares without voting rights. Each share entitles to one vote. To be validly adopted, each proposal must obtain an ordinary majority of the votes.

Validity of the Meeting

The Meeting acknowledged the correctness of the above statements, unanimously acknowledged that it is validly convened and composed and capable to deliberate, and resolved to start deliberating on the items on the agenda.

Resolution, deliberation and voting

The Meeting started the agenda of the Shareholders' Meeting, and the Chairman proposed the following resolutions and submitted them for deliberation and, where required, for a vote:

Ordinary part:

First agenda item

Communication and discussion of the annual report of the Board of Directors relating to the non-consolidated and consolidated annual accounts of the Company for the financial year ended on 31 December 2015, and of the report of the Statutory Auditor relating to the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2015.

The Chairman presented the annual report of the Board of Directors for the activities of the financial year ended on 31 December 2015, relating to both the non-consolidated annual accounts of the Company and to the consolidated annual accounts; this annual report also includes corporate governance statement. The Chairman also presented the report of the Statutory Auditor relating to the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2015.

Second agenda item

Communication and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2015 and approval of the allocation of the annual result as proposed by the Board of Directors.

The Chairman presented the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2015.

The Shareholders' Meeting resolved to approve the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2015, as well as the allocation of the annual result as proposed by the Board of Directors.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes and amounts to 24,693,265, representing 53.72% of the capital as at the opening of the meeting.

This resolution was adopted by the Meeting with 23,311,227 votes (96.40%) in favor, 972,069 votes (3.94%) against and 409,969 abstentions (1.66%).

Third agenda item

Communication and discussion of the report of the Statutory Auditor relating to the consolidated annual accounts of the Company for the financial year ended on 31 December 2015.

The Chairman presented the report of the Statutory Auditor relating to the consolidated annual accounts of the Company for the financial year ended on 31 December 2015.

Fourth agenda item

Communication and discussion of the consolidated annual accounts of the Company for the financial year ended on 31 December 2015.

The Chairman presented the consolidated annual accounts of the Company for the financial year ended on 31 December 2015.

Free translation for information purposes only

Fifth agenda item

Communication and approval of the remuneration report.

The Chairman presented the Company's Remuneration Report for the financial year ended on 31 December 2015.

The Shareholders' Meeting resolved to approve the Remuneration Report.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes and amounts to 24,693,265, representing 53.72% of the capital as at the opening of the meeting.

The resolution was taken by the Meeting with 13,811,700 votes (55.93%) in favor, 10,879,633 votes (44.06%) against and 1,932 abstentions (0.01%).

Sixth agenda item

Release from liability to be granted to the Directors and the Statutory Auditor for the performance of their duties in the course of the financial year ended 31 December 2015.

The Shareholders' Meeting resolved, by separate vote, to release each Director and the Statutory Auditor from any liability arising from the performance of their duties during the last financial year.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes and amounts to 24,693,265, representing 53.72% of the capital as at the opening of the meeting.

This resolution was adopted by the Meeting with 23,287,840 votes (94.31%) in favor, 995,127 votes (4.03%) against and 410,298 abstentions (1.66%).

Seventh agenda item

Remuneration of Directors.

Upon recommendation of the Company's Nomination and Remuneration Committee, the Shareholders' Meeting resolved that (a) the compensation (excluding expenses) of the non-executive Directors for the exercise of their mandate during the financial year ending 31 December 2016 is established as follows: (i) Chairman of the Board: €80,000; (ii) other non-executive Board members: €40,000 each; (iii) annual additional compensation for membership of a Board committee: €5,000; (iv) annual additional compensation for the chairmanship of a Board committee: €10,000; and (b) power of attorney be granted to the Board of Directors to determine the total remuneration package of the Managing Director (CEO) for his management function in the Company, it being understood that this remuneration shall include a compensation for the performance of his mandate as a Director of the Company.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes and amounts to 24,693,265, representing 53.72% of the capital as at the opening of the meeting.

This resolution was adopted by the Meeting with 24,679,442 votes (99.94%) in favor, 12,309 votes (0.05%) against and 1,514 abstentions (0.01%).

Eighth agenda item

Offer of warrants.

Upon recommendation of the Company's Nomination and Remuneration Committee, the Shareholders' Meeting (i) resolved to offer 100,000 warrants to Mr. Onno van de Stolpe, 15,000 warrants to Dr. Raj Parekh, and 7,500 warrants to each of Dr. Werner Cautreels, Dr. Harrold van Barlingen, Mr. Howard Rowe, Ms. Katrine Bosley and Dr. Christine Mummery, under warrant plans to be created by the Board of Directors for the benefit of Directors, employees and independent consultants of Galapagos and its affiliates within the framework of the authorized capital (jointly "**Warrant Plan 2016**"), the key conditions of which will be in line with previous warrant plans of the Company, (ii) empowered the Managing Director, as well as any other Director as regards the offer to the Managing Director, to implement this offer, and (iii) to the extent required, approved the offer of warrants to members of Galapagos' Executive Committee under Warrant Plan 2016 in accordance with Galapagos'

Free translation for information purposes only

remuneration policy and practices. In accordance with articles 520^{ter} and 556 of the Belgian Companies Code, the Shareholders' Meeting expressly approved the particular provisions of such Warrant Plan 2016 pursuant to which, in exceptional circumstances (including in the event of a change in control of the Company), all 900,000 warrants offered (to the extent accepted) under Warrant Plan 2016 can be exercised early, even before the third anniversary of their award.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes and amounts to 24,693,265, representing 53.72% of the capital as at the opening of the meeting.

This resolution was adopted by the Meeting with 16,465,536 votes (66.68%) in favor, 7,816,661 votes (31.66%) against and 411,068 abstentions (1.66%).

The resolutions of this Shareholders' Meeting relating to the issuance of warrants can only be implemented if the Belgian Financial Services and Markets Authority (FSMA) has communicated to the Company that it has no objections to make against the issuance of warrants as set forth in this agenda item.

Special part:

Nenth agenda item

Application of article 556 of the Belgian Companies Code.

In accordance with article 556 of the Belgian Companies Code, the Shareholders' Meeting resolved to approve, and to the extent required, ratify all of the provisions granting rights to third parties which could affect the assets of the Company, or could impose an obligation on the Company, where the exercise of those rights is dependent on a public takeover bid on the shares of the Company or a change of control in respect of the Company, as included in: (a) the License and Collaboration Agreement between Galapagos NV and Gilead Biopharmaceutics Ireland Unlimited Company dated 16 December 2015 (the "**License and Collaboration Agreement**") including, but not limited to, clause 15.6 (*Assignment; Industry Transaction; Acquired Programs*) of the License and Collaboration Agreement, entitling the counterparty (i) in the event of an industry transaction involving the Company, as a result of which a drug company of a certain minimum size acquires control over the Company, to terminate the Company's co-promotion rights, to disband all joint committees and undertake exclusive control of their activities; and (ii) in the event of a change of control as a result of which the Company acquires rights to an alternative product that would violate certain of Company's exclusivity obligations under the License and Collaboration Agreement, to require the Company to either divest or terminate this acquired program; (b) the Sublicense Agreement between Ambion, Inc. as licensor and the Company as licensee dated 18 December 2003 (as amended from time to time, the "**Ambion Sublicense Agreement**") including, but not limited to, section 9.4 (*Change in Ownership or Control*) of the Ambion Sublicense Agreement which requires the Company to obtain the counterparty's prior consent in the event of a change in control over the Company; and (c) Warrant Plan 2013 (B) and Warrant Plan 2014 (B), pursuant to which, in exceptional circumstances (including in the event of a change in control of the Company), all 180,000 warrants outstanding under these warrant plans can be exercised early, even before the third anniversary of their award. The Shareholders' Meeting granted a special power of attorney to each Director of the Company, as well as to Mr. Xavier Maes and Ms. Ellen Lefever, each acting individually and with the power of substitution, to file this resolution with the clerk's office of the Commercial Court of Antwerp, division of Mechelen, in accordance with article 556 of the Belgian Companies Code.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes and amounts to 24,693,265, representing 53.72% of the capital as at the opening of the meeting.

This resolution was adopted by the Meeting with 22,934,727 votes (92.88%) in favor, 1,755,282 votes (7.11%) against and 3,256 abstentions (0.01%).

Tenth agenda item

Miscellaneous.

In the context of the agenda of this Shareholders' Meeting, no miscellaneous items were tabled.

Closing

The agenda of this Annual Shareholders' Meeting was finished and the Meeting was closed by the Chairman at 3:45 p.m. CET.

Of which these minutes were drawn up.

Made on the date and place as set forth above.

The Meeting waived the Chairman's reading of the minutes. Subsequently, the members of the Bureau and the members of the Meeting who so desired, signed these minutes.

(Signed)

W. Cautreels
Chairman

(Signed)

O. van de Stolpe
Managing Director

(Signed)

J. Adriaenssens
Vote Counter

(Signed)

J. Bauters
Vote Counter

(Signed)

X. Maes
Secretary

GALAPAGOS

Naamloze Vennootschap
 Generaal De Wittelaan L11 A3, 2800 Mechelen, België
 Ondernemingsnummer: 0466.460.429
 RPR Antwerpen, afdeling Mechelen
 (de "Vennootschap")

Aanwezigheidslijst (aandelen)
 van de Gewone Algemene Vergadering van 26 april 2016

Naam	Aantal aandelen op naam	Aantal gedemat. aandelen	Volmacht aan	Handtekening	Aanwezig aantal aandelen
BNP Paribas Securities Services	-	4.672.663	General Counsel Galapagos NV		4.672.663
Citibank Europe plc (ADRs)	-	7.001.028	General Counsel Galapagos NV		7.001.028
Citibank Europe plc (OS)	-	1.439.923	General Counsel Galapagos NV		1.439.923
Gilead Biopharmaceutics Ireland Unlimited Company	6.760.701	-	General Counsel Galapagos NV		6.760.701
GlaxoSmithKline LLC	513.218	-	General Counsel Galapagos NV		513.218
Goodwin, E.	-	20.000	General Counsel Galapagos NV		20.000
Hoekema, A.	-	14.852	General Counsel Galapagos NV		14.852

Naam	Aantal aandelen op naam	Aantal gedemat. aandelen	Volmacht aan	Handtekening	Aanwezig aantal aandelen
KBC Asset Management NV	-	135.718	General Counsel Galapagos NV		135.718
Stichting Juridisch Eigendom Hoofbosch Beleggingsfonds	-	245.000	General Counsel Galapagos NV		245.000
Van de Stolpe, O.	-	538.289	General Counsel Galapagos NV		538.289
Wigerinck, P.	-	5.000	General Counsel Galapagos NV		5.000
FCP Liberté Santé	-	3.450	Adriaenssens, J.		3.450
Stichting Pensioenfonds PGB	-	16.089	Adriaenssens, J.		16.089
Caceis Bank	-	175.702	El Sayd, S.		175.702
City University of Hong Kong	-	30.200	El Sayd, S.		30.200
Deutsche Bank AG	-	350.296	El Sayd, S.		350.296
Deutsche X-Tracker MSCI EaFe Small Cap Hedged Equity ETF	-	3	El Sayd, S.		3
Investeringsforeningen Bankinvest Europa Small Cap Aktier	-	20.800	El Sayd, S.		20.800

Naam	Aantal aandelen op naam	Aantal gedemat. aandelen	Volmacht aan	Handtekening	Aanwezig aantal aandelen
Los Angeles City Employees Retirement System	-	282	El Sayd, S.		282
Kowloon Motor Bus Company (1933) Limited	-	18.400	El Sayd, S.		18.400
Metzler Investment GmbH	-	16.900	El Sayd, S.		16.900
Northern Trust Comp.	-	297.674	El Sayd, S.		297.674
Sime Darby Hong Kong Retirement	-	14.800	El Sayd, S.		14.800
State Street Bank Trust Company	-	2.350.925	El Sayd, S.		2.350.925
Stichting Pensioenfonds Horeca and Catering	-	322	El Sayd, S.		322
Trust Fund Advisors International Group Trust	-	319	El Sayd, S.		319
Ullico Diversified International Equity Fund L.P.	-	1.032	El Sayd, S.		1.032
Ullico International Small Cap Fund L.P.	-	4.121	El Sayd, S.		4.121
Vanguard Developed Markets Index Fund	-	255	El Sayd, S.		255


Naam	Aantal aandelen op naam	Aantal gedemat. aandelen	Volmacht aan	Handtekening	Aanwezig aantal aandelen
Van Herk Investments B.V.	-	3.422.647	Esveld, E.		/
P.S.C. Holding B.V.	-	200	Post, B.		200
Hermsen, P.	-	1.800	Wierda, A.		1.800
Bauters, J.	-	7.500	-		7.500
Broekhuizen, H.	-	50	-		/
Brugmans, M.	-	4.000	-		4.000
DeJongh, D.	-	100	-		100
Govaerts, J.	-	1	-		1
Hendrik, P.	-	30.090	-		/
Kremer, L.	-	200	-		/
Kremer-Eenschoten, M.	-	200	-		/

Naam	Aantal aandelen op naam	Aantal gedemat. aandelen	Volmacht aan	Handtekening	Aanwezig aantal aandelen
Martens, A.	-	1.000	-		1.000
Norg, R.	-	200	-		✓
Roorda, I.	-	1	-		1
Smink, J.	-	15.000	-		15.000
Snoeker, R.	-	850	-		850
Snoeker-Van der Plas, H.	-	850	-		850
Timmermans, J.-P.	-	500	-		500
Van Bommel	-	300	-		✓
Van Bommel-Schinkel	-	300	-		✓
Van den Dries, J.	-	1	-		1
Van Raamsdonk, P.	-	3.500	-		3.500

Galapagos NV – Bijlage bij de notulen van de Gewone Algemene Vergadering van 26 april 2016


Naam	Aantal aandelen op naam	Aantal gedemat. aandelen	Volmacht aan	Handtekening	Aanwezig aantal aandelen
Van Wagensveld, P.	-	60.000	-		/
Vereniging van Effectenbezitters VEB	-	1	-		/
Visser, J.	-	10.000	-		10.000
TOTAAL AANTAL AANDELEN					24.693.265

**Aanwezigheidslijst (warrants)
van de Gewone Algemene Vergadering van 26 april 2016**


Naam	Aantal warrants	Volmacht aan	Handtekening	Aanwezig aantal warrants
Vanhoutte, Frédéric	20.000	-		20.000
TOTAAL AANTAL WARRANTS				20.000



W. Cautreels
Voorzitter




O. van de Stolpe
Gedelegeerd Bestuurder



Stemopnemer



J. ADRIANESSENS
Stemopnemer



X. Maes
Secretaris